Fulgent Genetics Inc (FLGT)vsNovartis AG ADR (NVS)
FLGT
Fulgent Genetics Inc
$15.19
+2.64%
HEALTHCARE · Cap: $470.46M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 17434% more annual revenue ($56.58B vs $322.67M). NVS leads profitability with a 23.9% profit margin vs -18.8%. FLGT appears more attractively valued with a PEG of 1.32. NVS earns a higher WallStSmart Score of 51/100 (C-).
FLGT
Hold44
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.1%
Fair Value
$65.95
Current Price
$15.19
$50.76 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -5.5% — below average capital efficiency
Earnings declined 98.6%
Negative free cash flow — burning cash
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : FLGT
The strongest argument for FLGT centers on Price/Book. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : FLGT
The primary concerns for FLGT are Market Cap, Return on Equity, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
FLGT profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
FLGT carries more volatility with a beta of 0.89 — expect wider price swings.
FLGT is growing revenue faster at 9.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 44/100), backed by strong 23.9% margins. FLGT offers better value entry with a 65.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fulgent Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?